ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant.
Till HolstenAnnika BronsemaDominik SturmFelix SahmStefan RutkowskiUlrich SchüllerWilhelm WößmannUwe R KordesPublished in: Pediatric blood & cancer (2022)